Lubeluzole

Last updated
Lubeluzole
Lubeluzole.png
Clinical data
ATC code
  • none
Identifiers
  • (2S)-1-[4-(1,3-benzothiazol-2-yl-methylamino)piperidin-1-yl]-3-(3,4-difluorophenoxy)propan-2-ol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.233.379 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C22H25F2N3O2S
Molar mass 433.52 g·mol−1
3D model (JSmol)
  • CN(C1CCN(CC1)C[C@@H](COC2=CC(=C(C=C2)F)F)O)C3=NC4=CC=CC=C4S3
  • InChI=1S/C22H25F2N3O2S/c1-26(22-25-20-4-2-3-5-21(20)30-22)15-8-10-27(11-9-15)13-16(28)14-29-17-6-7-18(23)19(24)12-17/h2-7,12,15-16,28H,8-11,13-14H2,1H3/t16-/m0/s1 X mark.svgN
  • Key:OZFSWVOEXHGDES-INIZCTEOSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Lubeluzole (Prosynap) is a drug which acts as an indirect NMDA antagonist. It inhibits the release of glutamate, inhibits nitric oxide synthesis, and blocks calcium and sodium gated ion channels. [1] It has neuroprotective effects particularly in hypoxic conditions, [2] [3] and was developed for the treatment of stroke. [4] Trials showed it to be safe, effective and well tolerated at low doses, but higher doses produced the dangerous cardiac side effect of lengthening the QTc interval, [5] [6] which could potentially lead to heart failure, and so this meant that subsequent trials were limited to using only the low dose range. [7] Animal studies had shown lubeluzole to produce neuroprotective effects when administered for prolonged periods, but the aim of its developers was to produce a drug that would be effective for preventing damage from acute stroke, and so ultimately it failed to show sufficient efficacy in trials and development for medical use was halted. [8]

References

  1. ↑ Culmsee C, Junker V, Wolz P, Semkova I, Krieglstein J (January 1998). "Lubeluzole protects hippocampal neurons from excitotoxicity in vitro and reduces brain damage caused by ischemia". European Journal of Pharmacology. 342 (2–3): 193–201. doi:10.1016/s0014-2999(97)01499-4. PMID   9548385.
  2. ↑ Ashton D, Willems R, Wynants J, Van Reempts J, Marrannes R, Clincke G (January 1997). "Altered Na(+)-channel function as an in vitro model of the ischemic penumbra: action of lubeluzole and other neuroprotective drugs". Brain Research. 745 (1–2): 210–21. doi:10.1016/s0006-8993(96)01094-3. PMID   9037412. S2CID   27971291.
  3. ↑ Maiese K, TenBroeke M, Kue I (February 1997). "Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide". Journal of Neurochemistry. 68 (2): 710–4. doi: 10.1046/j.1471-4159.1997.68020710.x . PMID   9003060. S2CID   15532366.
  4. ↑ Grotta J (December 1997). "Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group". Stroke. 28 (12): 2338–46. doi:10.1161/01.str.28.12.2338. PMID   9412611.
  5. ↑ Hantson L, Tritsmans L, Crabbé R, Gheuens J, Van Rooy P (November 1997). "The safety and tolerability of single intravenous doses of lubeluzole (Prosynap) in healthy volunteers". International Journal of Clinical Pharmacology and Therapeutics. 35 (11): 491–5. PMID   9401829.
  6. ↑ Wood PL, Hawkinson JE (April 1997). "N-methyl-D-aspartate antagonists for stroke and head trauma". Expert Opinion on Investigational Drugs. 6 (4): 389–97. doi:10.1517/13543784.6.4.389. PMID   15989606.
  7. ↑ Hacke W, Lees KR, Timmerhuis T, Haan J, Hantson L, Hennerici M, Diener HC (1998). "Cardiovascular safety of lubeluzole (Prosynap(R)) in patients with ischemic stroke". Cerebrovascular Diseases. 8 (5): 247–54. doi:10.1159/000015861. PMID   9712921. S2CID   25262626.
  8. ↑ Gandolfo C, Sandercock P, Conti M (2002). "Lubeluzole for acute ischaemic stroke". The Cochrane Database of Systematic Reviews (1): CD001924. doi:10.1002/14651858.CD001924. PMID   11869612.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.